Innovative Hormone Tracking: Stanford Grads Launch $11M Wearable Solution

TL;DR

• Stanford graduates Jenny Duan and Abhinav Agarwal have raised $11.6 million to build Clair Health, a noninvasive wearable for continuous hormone tracking.
• The device is designed to monitor signals tied to inflammation, bloating, energy, cycle phase, irregular cycles, and perimenopause, with beta testing underway and a planned November launch.
• Clair is positioning the product as a jewelry-inspired, privacy-first women’s health tool, with preorders open and a price of $369 plus a $9.99 monthly subscription.

Stanford Grads Bet Big on Continuous Hormone Tracking

Two Stanford graduates are pushing women’s health wearables into a new category: continuous, noninvasive hormone monitoring. Jenny Duan and Abhinav Agarwal have raised $11.6 million for Clair Health, a startup building a wearable meant to help users understand hormonal patterns that traditional tests often miss.

The company’s pitch is simple but ambitious: make hormone data as accessible and continuous as heart-rate or sleep tracking. Clair says its device is aimed at surfacing insights connected to inflammation, bloating, energy levels, cycle phase, cycle irregularities, and perimenopause.

What Clair Health Is Building

Clair Health is developing a wrist-worn, jewelry-inspired device that uses noninvasive sensing rather than blood draws or urine tests. The startup is also pairing the wearable with software that translates the data into understandable health insights for users.

According to reporting on the company, Clair is focused on women’s health and is designed to provide continuous tracking of hormone dynamics in real time. The company has described its approach as privacy-first and research-backed.

Why This Matters

Hormone tracking has traditionally been fragmented, relying on occasional lab work, self-reported symptoms, or fertility-focused testing. Clair’s bet is that a wearable can close that gap by offering day-to-day visibility into patterns that may be relevant to menstrual-cycle changes and perimenopause.

That framing reflects a broader shift in digital health: moving from episodic measurements to continuous monitoring. If Clair’s system works as intended, it could give users a more detailed picture of how symptoms such as fatigue or bloating align with hormonal changes over time.

Funding and Backers

The company’s funding round was led by Khosla Ventures and included participation from a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, Anne Wojcicki, and Stephanie Coleman. Axios also reported the round at $11.6 million.

That investor mix suggests strong interest from both health-tech specialists and consumer-tech backers. It also signals that women’s health wearables remain a hot area for venture funding, especially products that promise more personalized data than conventional tools.

Product Timeline and Pricing

Clair is already testing the device with a closed group of beta users. The company plans to ship units in November, with the wearable priced at $369 and an accompanying $9.99 monthly subscription.

Preorders are already available, indicating the startup is moving from stealth-mode development toward an early commercial launch.

The Bigger Femtech Opportunity

Clair’s emergence comes amid growing demand for better tools in femtech, especially products that address gaps in cycle health, fertility, and midlife hormonal transitions. The startup’s emphasis on perimenopause is notable, since that stage has historically been under-measured and under-served by consumer health technology.

By focusing on continuous, noninvasive tracking, Clair is trying to position itself as more than a fertility tool. The company’s message is broader: hormone fluctuations can affect energy, symptoms, and daily well-being across a wide range of life stages.

What to Watch Next

The key question now is whether Clair can translate its hardware and algorithms into clinically useful, easy-to-understand insights. The startup has made bold claims about continuous hormone monitoring, but the market will ultimately judge it on accuracy, comfort, and whether users find the data actionable in real life.

If Clair’s November launch stays on schedule, the next few months will show whether this Stanford-built wearable can turn a long-standing women’s health pain point into a compelling consumer product.

AndroGuider Team

Articles written by the AndroGuider team. We try to make them thorough and informational while being easy to read.